Home › Funds › ANTIPODES PARTNERS Ltd › GMED
ANTIPODES PARTNERS Ltd position in GMED
GLOBUS MED INC · Health Care
ANTIPODES PARTNERS Ltd reported holding 931,430 shares of GMED (GLOBUS MED INC) in its Q3 2026 13F filing — a position valued at US$69.8M, representing 1.29% of its reported portfolio and ranking #39 among its reported holdings. ANTIPODES PARTNERS Ltd has disclosed GMED holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ANTIPODES PARTNERS Ltd's GMED position evolved
ANTIPODES PARTNERS Ltd first disclosed a stake in GMED in Q1 2025 at 1,747 shares (US$128K). The position peaked in Q4 2025 at 906,833 shares, worth US$79.2M. Across 7 filings, ANTIPODES PARTNERS Ltd increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 931,430 shares valued at US$69.8M — an increase of 25,446 shares quarter over quarter.. Notable position changes include a 49020% increase in Q3 2025 (shares rose 52% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 1.75K | $127.89K | New |
| Q2 2025 | 1.81K | $107.07K | Add |
| Q3 2025 | 891.04K | $51.03M | Add |
| Q4 2025 | 906.83K | $79.18M | Add |
| Q1 2026 | 897.61K | $77.34M | Reduce |
| Q2 2026 | 905.98K | $71.58M | Add |
| Q3 2026 | 931.43K | $69.76M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GMED and 13F data
GMED (GLOBUS MED INC) is a Health Care company. 36 other funds we track also report a position in GMED — the largest reported positions include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (US$338.1M), Sculptor Capital LP (US$237.0M), Boston Trust Walden Corp (US$123.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GMED
- KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC 4.28M sh · $338.14M · Q2 2026
- Sculptor Capital LP 3.00M sh · $237.03M · Q2 2026
- Boston Trust Walden Corp 1.64M sh · $123.07M · Q3 2026
- GW&K Investment Management, LLC 1.47M sh · $110.29M · Q3 2026
- GENEVA CAPITAL MANAGEMENT LLC 1.25M sh · $93.58M · Q3 2026
- Madison Avenue Partners, LP 935.22K sh · $73.89M · Q2 2026
More on ANTIPODES PARTNERS Ltd
FAQ
How long has ANTIPODES PARTNERS Ltd held GMED?
ANTIPODES PARTNERS Ltd has disclosed GMED holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is ANTIPODES PARTNERS Ltd's current position in GMED?
As of Q3 2026, ANTIPODES PARTNERS Ltd holds 931.43K shares of GMED (GLOBUS MED INC), valued at $69.76M, representing 1.29% of its reported portfolio and ranking #39.
Has ANTIPODES PARTNERS Ltd been buying or selling GMED?
In the latest 13F filing (Q3 2026), ANTIPODES PARTNERS Ltd increased its position in GMED. The position peaked in Q4 2025 at 906.83K shares.
Which other funds hold GMED?
Other major institutional holders of GMED include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC, Sculptor Capital LP, Boston Trust Walden Corp, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.